Market News AIOpen the app

The FDA has given the green light for Regeneron's drug Livsayis to treat generalized myasthenia gravis.

TrialRead the original at investor.regeneron.com
Good for REGN

Regeneron won approval for Livsayis, its first approved siRNA therapy and first neurology medicine. The approval covers only adults with antibody-positive gMG, but its 4-times-a-year dosing and trial results make this a favorable addition.

REGN · Regeneron Pharmaceuticals

AI read · Good for REGN

The AI's read

This gives Regeneron an approved medicine in a new area of care. Its dosing schedule is unique among gMG treatments, and the Phase 3 trial showed rapid, lasting disease control. The approval covers adults with a specific antibody-positive form of the disease, not everyone with gMG.

Get alerts for REGN

Follow Regeneron Pharmaceuticals (REGN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for REGN
Free on the App Store and Google Play, or on the web.